0001562180-23-008590.txt : 20231229 0001562180-23-008590.hdr.sgml : 20231229 20231229182520 ACCESSION NUMBER: 0001562180-23-008590 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231229 FILED AS OF DATE: 20231229 DATE AS OF CHANGE: 20231229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Antonijevic Irina CENTRAL INDEX KEY: 0001926476 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41477 FILM NUMBER: 231528998 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Ltd. CENTRAL INDEX KEY: 0001935979 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 FORMER COMPANY: FORMER CONFORMED NAME: Biohaven Research Ltd. DATE OF NAME CHANGE: 20220629 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2023-12-29 false 0001935979 Biohaven Ltd. BHVN 0001926476 Antonijevic Irina C/O BIOHAVEN LTD. 215 CHURCH STREET NEW HAVEN CT 06510 true false false false false Common Shares 2023-12-29 4 M false 11000.00 0.00 A 13535.00 D Common Shares 2023-12-29 4 S false 11000.00 41.7875 D 2535.00 D Stock Options (Right to Buy) 7.00 2023-12-29 4 M false 11000.00 0.00 D 2032-10-03 Common Shares 11000.00 114000.00 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.74 - $41.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. /s/ George Clark, Attorney-in-Fact 2023-12-29